doi: 10.1016/S2213-8587(21)00311-9.
Epub 2021 Nov 30.
Is the impact of add on heart failure therapy influenced by background therapy?
Affiliations
- PMID: 34861151
- DOI: 10.1016/S2213-8587(21)00311-9
Item in Clipboard
Is the impact of add on heart failure therapy influenced by background therapy?
Lancet Diabetes Endocrinol.
2022 Jan.
No abstract available
Conflict of interest statement
We declare no competing interests.
Comment in
-
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. Lancet Diabetes Endocrinol. 2022. PMID: 34861154
Similar articles
-
Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions.Eur J Heart Fail. 2004 Mar 1;6(2):235-43. doi: 10.1016/j.ejheart.2003.08.003. Eur J Heart Fail. 2004. PMID: 14984732
-
Is aspirin safe in heart failure? more data.Heart. 1996 Apr;75(4):426. doi: 10.1136/hrt.75.4.426. Heart. 1996. PMID: 8705776 Free PMC article. No abstract available.
-
Using carvedilol to treat heart failure.Crit Care Nurse. 2002 Apr;22(2):36-40, 42-6, 48 passim. Crit Care Nurse. 2002. PMID: 11961943 Review. No abstract available.
-
Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes.J Cardiovasc Pharmacol Ther. 2004 Dec;9(4):243-55. doi: 10.1177/107424840400900404. J Cardiovasc Pharmacol Ther. 2004. PMID: 15678243 Review.
-
Impact of pharmacotherapy on lymphocyte volumes and activity of the Na+/H+ exchanger in patients with congestive heart failure.Methods Find Exp Clin Pharmacol. 2001 Sep;23(7):409-13. doi: 10.1358/mf.2001.23.7.662128. Methods Find Exp Clin Pharmacol. 2001. PMID: 11771856 Clinical Trial.
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
